|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary |  |
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
Cash-to-Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. A high ratio indicates that a company is better able to pay back its debt, and is thus able to take on more debt if necessary.
Equity-to-Asset ratio is calculated as total stockholders equity divided by its total assets. Equity-to-Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity-to-Asset ratio (more leveraged) may have higher ROE % because of the leverage.
A high Debt-to-Equity ratio generally means that a company has been aggressive in financing its growth with debt.
The Piotroski F-Score is used to determine the strength of a firm's financial position, with 9 being the best and 0 being the worst.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business.
Dividend yield is a way to measure how much cash flow you are getting for each dollar invested in an equity position.
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise. Net Income is a company's total profit. Net income is calculated by taking revenues and adjusting for the cost of doing business, depreciation, interest, taxes and other expenses.
Cash & equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash. Long-Term Debt* consists of loans and obligations lasting over one year.
Operating margin % measures how much profit a company makes on a dollar of sales. Operating Margin % is calculated as Operating Income divided by Revenue.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock. In calculating earnings per share without non-recurring items, the dividends of preferred stocks and Non Operating Income need to subtracted from the total net income first.
Dividends per Share is the amount of dividends that the shareholders of a company receive on a per-share basis. It is calculated using the total dividends paid out to shareholders over one fiscal year and the number of shares outstanding.
Free Cash flow per Share is the amount of Free cash flow per outstanding share of the company's stock.
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
These valuation metrics should give you a sense of reasonable prices, but be careful with them. Always seek to understand why a valuation is changing over time.
The price-to-earnings ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
The price-to-book ratio measures the valuation of the stock relative to the underlying asset of the company.
The price-to-sales ratio is a valuation ratio that compares a company’s stock price to its revenues. The price-to-sales ratio is an indicator of the value placed on each dollar of a company’s sales or revenues.
Price-to-free-cash-flow is very similar to the valuation metric of price-to-operating-cash-flow but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
Enterprise value of a company divided by its trailing 12 months earnings before interest and taxes (EBIT).
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
In these charts the 10-year valuation bands of the price-to-earnings ratio (PE Ratio), price-to-book ratio (PB Ratio), price-to-sales ratio (PS Ratio) and price-to-operating-cash-flow ratio (POCF) are drawn together with the historical stock prices. For example, the upper line of the PE band is where the stock price would have been if it were always traded at the maximum PE ratio of the past 10 years. The lower line of the PE band is where the stock price would have been if it were always traded at the lowest PE ratio of the past 10 years. It is always better if the stock price is close to the lower line, which indicates a lower valuation.
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
GuruFocus conducted a thorough checkup using a checklist of 32 items that cover the areas of financial strength, profitability, growth, and valuation of each company. The purpose of Warning Signs is to warn you that the company may have red flags in certain areas, helping to avoid overlooking them. These warning signs do not necessarily mean you should not invest in the stock. But you should be aware of them before you invest.
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
| Company | Financial Strength | Cash-to-Debt | Equity-to-Asset | Debt-to-Equity | Interest Coverage | Piotroski F-Score | Altman Z-Score | Beneish M-Score | WACC % | ROIC % | |
| 10/10 | 86.52 | 0.89 | 0.01 | 70.37 | 3 | 26.50 | -0.24 | 2.26 | 41.43 | ||
| 9/10 | 3.09 | 0.78 | 0.09 | 80.15 | 5 | 6.82 | -2.29 | 4.92 | 14.36 | ||
| 8/10 | 48.16 | 0.89 | 0.02 | 0.00 | 3 | 8.55 | -2.84 | 9.19 | -10.81 | ||
| 8/10 | 1852.20 | 0.96 | 0.00 | N/A | N/A | 0.00 | 0.00 | 10.34 | -2119.75 | ||
| 8/10 | 0.91 | 0.65 | 0.13 | 36.13 | 8 | 8.35 | -2.51 | 3.70 | 8.66 | ||
| 8/10 | 270.66 | 0.96 | 0.00 | N/A | 2 | 0.00 | 0.00 | -0.99 | -1689.99 | ||
| 8/10 | 3.76 | 0.72 | 0.10 | 0.00 | 2 | 12.49 | -2.35 | 6.87 | -11.10 | ||
| 7/10 | 6.94 | 0.82 | 0.14 | N/A | 2 | 0.00 | 0.00 | 4.90 | -351.97 | ||
| 7/10 | 0.44 | 0.82 | 0.13 | 8.54 | 6 | 7.24 | -2.36 | 5.25 | 2.24 | ||
| 7/10 | 17.65 | 0.84 | 0.06 | N/A | 3 | 6.45 | 0.00 | 15.09 | -731.44 | ||
| 7/10 | 0.58 | 0.58 | 0.30 | 6.17 | 9 | 3.94 | -2.38 | 5.48 | 6.03 | ||
| 7/10 | 8.57 | 0.85 | 0.11 | 0.00 | 3 | 0.00 | 0.00 | 9.53 | -220.80 | ||
| 6/10 | 1.94 | 0.89 | 0.08 | N/A | 3 | 3.31 | -2.26 | 9.40 | -23.11 | ||
| 6/10 | 3.36 | 0.56 | 0.29 | 0.00 | 4 | -1.53 | -3.42 | 15.90 | -59.83 | ||
| 5/10 | 2.02 | 0.03 | 11.28 | 0.00 | 5 | 4.91 | -1.90 | 6.62 | -7.75 | ||
| 5/10 | 0.14 | 0.46 | 0.70 | 6.57 | 6 | 4.00 | -2.17 | 8.19 | 6.80 | ||
| 4/10 | 6.55 | 0.64 | 0.19 | N/A | N/A | -5.31 | 0.00 | 9.50 | -833.52 | ||
| 4/10 | 1.01 | 0.39 | 1.20 | 0.00 | 2 | -5.41 | -3.12 | 17.29 | -107.72 | ||
| 4/10 | 1.26 | 0.11 | 3.29 | 5.56 | 6 | -7.12 | -1.90 | 9.18 | 56.07 | ||
| 2/10 | 0.38 | -0.35 | -2.97 | 0.00 | 3 | -7.11 | -0.41 | 7.23 | -90.89 |
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
| Company | Profitability Rank | Operating Margin % | Net Margin % | ROE % | ROA % | Price-to-Free-Cash-Flow | ROC (Joel Greenblatt) % | 3-Year Revenue Growth % | 3-Year EBITDA Growth % | 3-Year EPS w/o NRI Growth % | |
| 10/10 | 18.79 | 17.96 | 15.75 | 7.11 | 51.97 | 26.72 | 15.70 | 12.20 | 6.40 | ||
| 10/10 | 17.09 | 13.90 | 2.99 | 2.48 | 56.12 | 18.26 | 11.60 | -6.30 | -18.40 | ||
| 9/10 | 27.20 | 31.94 | 15.70 | 12.28 | 21.06 | 50.28 | -4.90 | -18.80 | -15.10 | ||
| 9/10 | 32.37 | 26.12 | 12.04 | 7.65 | 535.09 | 30.95 | 39.70 | 37.00 | 38.60 | ||
| 8/10 | 14.04 | 17.31 | 11.43 | 6.59 | 36.35 | 79.10 | 2.10 | 7.10 | -13.50 | ||
| 8/10 | -3.77 | -8.91 | -6.04 | -4.43 | 0.00 | -12.57 | 13.60 | -44.80 | -68.20 | ||
| 4/10 | -23.54 | -27.92 | -3.97 | -3.46 | 0.00 | -57.26 | -47.40 | 0.00 | 0.00 | ||
| 4/10 | 8.40 | 41.95 | 23.26 | 20.74 | 0.00 | 59.29 | 55.00 | 0.00 | 0.00 | ||
| 3/10 | -4.91 | -11.49 | 0.00 | -6.58 | 0.00 | -29.78 | 35.20 | 35.50 | 42.30 | ||
| 3/10 | -264.71 | -229.11 | -21.15 | -18.53 | 0.00 | -201.34 | -5.20 | -46.50 | -37.20 | ||
| 3/10 | -76.01 | -71.78 | 0.00 | -37.25 | 0.00 | -211.38 | 118.80 | 8.40 | 15.30 | ||
| 3/10 | 21.63 | 18.31 | Neg. E | 25.32 | 9.51 | 962.94 | 5.00 | 0.00 | 0.00 | ||
| 2/10 | 0.00 | 0.00 | -55.39 | -47.51 | 0.00 | -477.65 | 0.00 | 34.10 | 42.00 | ||
| 2/10 | -100.41 | -100.62 | -50.09 | -29.48 | 0.00 | -78.72 | -46.00 | 0.00 | 0.00 | ||
| 1/10 | -2039.73 | -1974.51 | 0.00 | -117.79 | 0.00 | -1029.63 | 0.00 | 0.00 | 0.00 | ||
| 1/10 | -134.40 | -149.47 | -112.59 | -52.61 | 0.00 | -205.48 | -20.70 | -41.10 | -39.10 | ||
| 1/10 | 0.00 | 0.00 | -44.10 | -34.18 | 0.00 | -6193.15 | 0.00 | 0.00 | 0.00 | ||
| 1/10 | 0.00 | 0.00 | -32.65 | -28.44 | 0.00 | -2570.33 | 0.00 | -20.80 | -17.00 | ||
| 0/10 | -7273.41 | -6496.82 | -40.78 | -37.43 | 0.00 | -1141.38 | 0.00 | 32.10 | 10.70 | ||
| 0/10 | 0.00 | 0.00 | -30.30 | -28.99 | 0.00 | -9014.93 | 0.00 | 16.40 | 20.30 |
| Company | PE Ratio | PB Ratio | PS Ratio | Price-to-Intrinsic-Value-Projected-FCF | Price-to-Intrinsic-Value-DCF (Earnings Based) | Price-to-Median-PS-Value | Price-to-Peter-Lynch-Fair-Value | Price-to-Graham-Number | Earnings Yield (Joel Greenblatt) % | Forward Rate of Return (Yacktman) % | |
| At Loss | 374.62 | 18.16 | 0.00 | 0.00 | 0.31 | 0.00 | 0.00 | -0.50 | 0.00 | ||
| At Loss | 1.10 | 10.63 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -204.08 | 0.00 | ||
| At Loss | 2.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -34.60 | 0.00 | ||
| At Loss | 1.29 | 8.94 | 0.45 | 0.00 | 0.00 | 0.00 | 0.00 | -7.01 | 0.00 | ||
| At Loss | 4.62 | 4.28 | 0.00 | 0.00 | 0.81 | 0.00 | 0.00 | -29.24 | 0.00 | ||
| At Loss | 3.49 | 463.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -22.22 | 0.00 | ||
| At Loss | 1.77 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -46.30 | 0.00 | ||
| At Loss | 0.86 | 7.48 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -32.89 | 0.00 | ||
| At Loss | 1.60 | 2.85 | 0.00 | 0.00 | 0.23 | 0.00 | 0.00 | -54.95 | 0.00 | ||
| At Loss | 0.00 | 1.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -40.98 | 0.00 | ||
| At Loss | 1.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -232.56 | 0.00 | ||
| At Loss | 7.16 | 10.72 | 2.58 | 0.00 | 0.83 | 0.00 | 0.00 | -0.24 | -10.94 | ||
| At Loss | 0.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3333.33 | 0.00 | ||
| 9.14 | 18.22 | 1.66 | 0.00 | 0.00 | 0.32 | 0.00 | 0.00 | 14.29 | 0.00 | ||
| 13.93 | 2.02 | 4.44 | 0.80 | 0.42 | 0.59 | 0.00 | 1.10 | 9.42 | 9.70 | ||
| 29.75 | 4.49 | 5.34 | 2.68 | 1.81 | 0.63 | 3.40 | 10.03 | 4.16 | 10.19 | ||
| 30.27 | 5.41 | 12.61 | 0.00 | 0.00 | 0.33 | 0.00 | 3.06 | 1.32 | 0.00 | ||
| 31.41 | 3.27 | 5.45 | 2.17 | 0.00 | 2.78 | 0.00 | 12.15 | 3.95 | -2.88 | ||
| 57.74 | 6.55 | 15.08 | 6.86 | 0.00 | 0.00 | 2.24 | 5.64 | 2.26 | 20.23 | ||
| 74.91 | 2.31 | 10.13 | 2.34 | 3.00 | 0.54 | 0.00 | 6.08 | 1.98 | 1.15 |
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
Per Share Data | |||||||||||||||||
Dec11 |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
TTM | Fiscal Period | |||
0.08 |
0.10 |
0.04 |
0.02 |
0.01 |
0.01 |
0.01 |
0.10 |
0.01 |
0.26 |
1.15 |
1.82 |
2.77 |
2.69 |
Revenue per Share | |||
-3.50 |
-3.84 |
-2.00 |
-2.59 |
-2.89 |
-3.09 |
-3.94 |
-3.81 |
-3.60 |
-4.47 |
-3.78 |
-4.13 |
-3.44 |
-2.96 |
EBITDA per Share | |||
-3.77 |
-4.08 |
-2.10 |
-2.69 |
-2.97 |
-3.14 |
-3.99 |
-3.86 |
-3.67 |
-4.65 |
-4.07 |
-4.67 |
-3.60 |
-3.06 |
EBIT per Share | |||
-6.25 |
-8.12 |
0.02 |
-3.24 |
-3.02 |
-3.18 |
-4.01 |
-3.94 |
-3.67 |
-4.86 |
-4.17 |
-4.90 |
-3.83 |
-1.94 |
Earnings per Share (Diluted) | |||
-6.32 |
-10.07 |
-2.99 |
-3.24 |
-3.03 |
-2.84 |
-3.89 |
-3.94 |
-3.67 |
-4.86 |
-4.17 |
-4.14 |
-2.95 |
-3.36 |
EPS without NRI | |||
-- |
-- |
-- |
-- |
-- |
-- |
-3.70 |
-5.08 |
-4.11 |
-4.70 |
-4.88 |
-4.78 |
-4.13 |
-2.14 |
Owner Earnings per Share (TTM) | |||
-3.98 |
-5.47 |
-3.06 |
-3.20 |
-2.42 |
-2.25 |
-3.26 |
-11.59 |
-2.52 |
-3.15 |
-3.44 |
-2.71 |
-2.64 |
-2.05 |
Free Cash Flow per Share | |||
-3.96 |
-5.42 |
-2.69 |
-2.84 |
-2.29 |
-2.13 |
-3.17 |
-2.88 |
-2.44 |
-3.08 |
-3.28 |
-2.66 |
-2.56 |
-2.00 |
Operating Cash Flow per Share | |||
4.13 |
0.57 |
0.22 |
7.19 |
8.92 |
6.48 |
7.75 |
4.76 |
5.54 |
6.31 |
3.14 |
4.14 |
2.89 |
1.76 |
Cash per Share | |||
-21.66 |
-30.20 |
-8.88 |
7.42 |
8.95 |
6.18 |
7.36 |
3.94 |
4.31 |
5.41 |
0.96 |
0.15 |
-1.72 |
-1.55 |
Book Value per Share | |||
-21.66 |
-30.20 |
-8.88 |
7.42 |
8.95 |
6.18 |
7.36 |
3.94 |
4.31 |
2.26 |
-1.87 |
-1.21 |
-1.84 |
-1.63 |
Tangible Book per Share | |||
9.61 |
14.83 |
1.44 |
0.15 |
0.30 |
0.19 |
0.05 |
-- |
0.56 |
3.07 |
4.53 |
5.08 |
5.44 |
4.61 |
Total Debt per Share | |||
-- |
-- |
-- |
16.94 |
34.16 |
20.70 |
35.75 |
20.13 |
16.23 |
28.34 |
16.32 |
18.46 |
8.79 |
3.65 |
Month End Stock Price | |||
7.18 |
7.18 |
17.74 |
19.39 |
24.34 |
28.12 |
30.10 |
36.17 |
43.46 |
58.01 |
67.51 |
72.71 |
84.60 |
104 |
Shares Outstanding (Diluted Average) | |||
Ratios | |||||||||||||||||
Dec11 |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
TTM | Fiscal Period | |||
-- |
-- |
-- |
-669 |
-34.21 |
-41.49 |
-54.09 |
-68.80 |
-85.92 |
-94.06 |
-127 |
-879 |
-- |
-- | ROE % | |||
-- |
-- |
-- |
-293 |
-8.96 |
-12.39 |
-11.13 |
-13.46 |
-22.79 |
-17.95 |
-7.45 |
-7.29 |
-- |
-- | ROE % Adjusted to Book Value | |||
-112 |
-218 |
-291 |
-58.50 |
-31.38 |
-37.18 |
-48.23 |
-54.62 |
-56.27 |
-53.20 |
-44.96 |
-64.04 |
-61.11 |
-37.25 |
ROA % | |||
-- |
-- |
-- |
-669 |
-34.21 |
-41.49 |
-54.09 |
-68.80 |
-85.92 |
-148 |
-2,539 |
-- |
-- |
-- | Return-on-Tangible-Equity | |||
-112 |
-218 |
-291 |
-58.50 |
-31.38 |
-37.18 |
-48.23 |
-54.62 |
-56.27 |
-66.99 |
-67.72 |
-89.30 |
-69.08 |
-37.94 |
Return-on-Tangible-Asset | |||
-321 |
-380 |
-350 |
-311 |
-371 |
-582 |
-1,211 |
-1,171 |
-571 |
-610 |
-474 |
-528 |
-390 |
-211 |
ROC (Joel Greenblatt) % | |||
-87.13 |
-- |
-- |
-66.42 |
-32.41 |
-39.33 |
-52.29 |
-59.48 |
-64.59 |
-56.24 |
-48.98 |
-69.94 |
-67.97 |
-67.54 |
ROCE % | |||
-- |
-- |
-- |
-- |
-- |
-- |
3.65 |
0.67 |
3.71 |
8.51 |
0.92 |
4.06 |
0.66 |
-13.34 |
5-Year RORE % | |||
-- |
-14.98 |
-7.94 |
44.06 |
-539 |
68.05 |
43,081 |
-161 |
-68.84 |
-44.56 |
-18.39 |
-2.05 |
-92.29 |
49.70 |
1-Year ROIIC % | |||
-175 |
-64.01 |
-43.53 |
-127 |
-267 |
-331 |
-622 |
-547 |
-327 |
-146 |
-87.09 |
-94.58 |
-99.84 |
-90.89 |
ROIC % | |||
-- |
-- |
31.37 |
10.48 |
8.34 |
8.53 |
14.10 |
11.13 |
6.08 |
8.19 |
6.46 |
6.38 |
5.85 |
7.23 |
WACC % | |||
25.79 |
33.01 |
22.99 |
73.52 |
19.80 |
15.65 |
12.66 |
2.35 |
-- |
12.55 |
2.34 |
4.43 |
4.32 |
4.77 |
Effective Interest Rate on Debt % | |||
99.10 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
68.88 |
69.91 |
61.03 |
68.23 |
69.79 |
Gross Margin % | |||
-4,980 |
-6,023 |
-6,195 |
-13,590 |
-24,106 |
-26,385 |
-44,846 |
-3,825 |
-39,821 |
-1,782 |
-353 |
-205 |
-95.00 |
-76.01 |
Operating Margin % | |||
-8,054 |
-8,125 |
-8,500 |
-16,427 |
-24,492 |
-29,757 |
-46,026 |
-3,823 |
-38,603 |
-1,841 |
-362 |
-269 |
-138 |
-71.78 |
Net Margin % | |||
-4,504 |
-3,839 |
-5,738 |
-13,105 |
-23,430 |
-28,914 |
-45,291 |
-3,695 |
-37,898 |
-1,692 |
-328 |
-226 |
-124 |
-105 |
EBITDA Margin % | |||
-5,128 |
-5,472 |
-8,790 |
-16,201 |
-19,666 |
-21,099 |
-37,392 |
-11,243 |
-26,487 |
-1,192 |
-298 |
-148 |
-95.48 |
-75.86 |
FCF Margin % | |||
-0.44 |
-0.49 |
-0.16 |
0.02 |
0.03 |
0.03 |
0.01 |
-- |
0.13 |
0.57 |
4.74 |
33.21 |
-3.16 |
-2.97 |
Debt-to-Equity | |||
-3.89 |
-16.15 |
-6.96 |
0.92 |
0.92 |
0.87 |
0.91 |
0.64 |
0.66 |
0.52 |
0.13 |
0.02 |
-0.32 |
-0.35 |
Equity-to-Asset | |||
1.73 |
7.93 |
1.13 |
0.02 |
0.03 |
0.03 |
0.01 |
-- |
0.09 |
0.30 |
0.61 |
0.72 |
1.00 |
1.05 |
Debt-to-Asset | |||
4.89 |
17.15 |
7.96 |
0.08 |
0.08 |
0.13 |
0.09 |
0.36 |
0.34 |
0.48 |
0.87 |
0.98 |
1.32 |
1.35 |
Liabilities-to-Assets | |||
1.38 |
2.69 |
3.42 |
0.36 |
0.13 |
0.12 |
0.10 |
1.43 |
0.15 |
1.99 |
8.69 |
14.54 |
30.12 |
36.22 |
Gross-Profit-to-Asset % | |||
-- |
3.64 |
-3.68 |
0.34 |
-0.56 |
0.27 |
0.70 |
-0.08 |
-0.50 |
0.47 |
-6.80 |
0.65 |
2.04 |
-37.86 |
Degree of Financial Leverage | |||
0.01 |
0.03 |
0.03 |
0.00 |
0.00 |
0.00 |
0.00 |
0.01 |
0.00 |
0.03 |
0.12 |
0.24 |
0.44 |
0.52 |
Asset Turnover | |||
-- |
38.18 |
88.74 |
250 |
228 |
123 |
123 |
1,324 |
23,862 |
43.56 |
12.14 |
20.22 |
30.42 |
47.54 |
Days Sales Outstanding | |||
56,721 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
791 |
181 |
53.51 |
45.05 |
38.73 |
Days Payable | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
450 |
125 |
101 |
157 |
278 |
Days Inventory | |||
-56,721 |
38.18 |
88.74 |
250 |
228 |
123 |
123 |
1,324 |
23,862 |
-298 |
-44.22 |
67.30 |
142 |
287 |
Cash Conversion Cycle | |||
-- |
9.56 |
4.11 |
1.46 |
1.60 |
2.96 |
2.98 |
0.28 |
0.02 |
8.38 |
30.06 |
18.05 |
12.00 |
7.68 |
Receivables Turnover | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
0.81 |
2.92 |
3.63 |
2.33 |
1.31 |
Inventory Turnover | |||
0.01 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
0.31 |
0.30 |
0.39 |
0.32 |
0.30 |
COGS-to-Revenue | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
0.38 |
0.10 |
0.11 |
0.14 |
0.23 |
Inventory-to-Revenue | |||
0.27 |
0.45 |
10.50 |
18.21 |
11.09 |
11.57 |
10.02 |
84.48 |
7.82 |
0.28 |
0.13 |
0.02 |
0.03 |
0.02 |
Capex-to-Revenue | |||
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
Income Statement | |||||||||||||||||
Dec11 |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
TTM | Fiscal Period | |||
0.56 |
0.72 |
0.62 |
0.38 |
0.30 |
0.30 |
0.26 |
3.73 |
0.41 |
15.33 |
77.80 |
133 |
234 |
257 |
Revenue | |||
0.01 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
4.77 |
23.41 |
51.67 |
74.36 |
77.63 |
Cost of Goods Sold | |||
0.55 |
0.72 |
0.62 |
0.38 |
0.30 |
0.30 |
0.26 |
3.73 |
0.41 |
10.56 |
54.39 |
80.90 |
160 |
179 |
Gross Profit | |||
99.10 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
68.88 |
69.91 |
61.03 |
68.23 |
69.79 |
Gross Margin % | |||
5.56 |
11.20 |
11.01 |
19.04 |
25.09 |
29.08 |
37.40 |
53.86 |
62.01 |
152 |
199 |
220 |
292 |
290 |
Selling, General, & Admin. Expense | |||
22.74 |
32.71 |
27.83 |
33.39 |
47.53 |
50.38 |
80.36 |
92.50 |
103 |
126 |
116 |
101 |
79.41 |
77.24 |
Research & Development | |||
-- |
-- |
-- |
-- |
-0.00 |
0.00 |
-0.00 |
-- |
0.00 |
6.08 |
13.99 |
32.09 |
10.36 |
7.39 |
Other Operating Expense | |||
28.29 |
43.90 |
38.84 |
52.43 |
72.62 |
79.46 |
118 |
146 |
165 |
284 |
329 |
353 |
382 |
375 |
Total Operating Expense | |||
-27.74 |
-43.19 |
-38.23 |
-52.05 |
-72.32 |
-79.16 |
-117 |
-143 |
-164 |
-273 |
-275 |
-272 |
-222 |
-195 |
Operating Income | |||
-4,980 |
-6,023 |
-6,195 |
-13,590 |
-24,106 |
-26,385 |
-44,846 |
-3,825 |
-39,821 |
-1,782 |
-353 |
-205 |
-95.00 |
-76.01 |
Operating Margin % | |||
0.02 |
0.01 |
0.00 |
0.04 |
0.23 |
1.17 |
1.41 |
4.02 |
5.53 |
4.32 |
0.34 |
4.89 |
13.29 |
12.24 |
Interest Income | |||
-17.79 |
-28.96 |
-15.16 |
-10.67 |
-1.19 |
-1.08 |
-0.46 |
-0.04 |
-- |
-15.15 |
-6.27 |
-16.47 |
-19.36 |
-23.07 |
Interest Expense | |||
-17.78 |
-28.95 |
-15.16 |
-10.63 |
-0.96 |
0.09 |
0.95 |
3.98 |
5.53 |
-10.83 |
-5.94 |
-11.58 |
-6.07 |
-10.83 |
Net Interest Income | |||
0.65 |
13.88 |
0.94 |
-0.24 |
-0.20 |
-10.20 |
-4.04 |
-0.91 |
-0.50 |
-0.72 |
-0.70 |
-71.97 |
-95.28 |
-95.37 |
Other Income (Expense) | |||
-44.86 |
-58.26 |
-52.45 |
-62.92 |
-73.48 |
-89.27 |
-121 |
-140 |
-159 |
-285 |
-281 |
-356 |
-324 |
-302 |
Pre-Tax Income | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-3.00 |
-- |
2.62 |
-- |
-0.70 |
-0.30 |
-1.50 |
Tax Provision | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-2.15 |
-- |
0.92 |
-- |
-0.20 |
-0.09 |
-0.50 |
Tax Rate % | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-0.00 |
-- |
119 |
Other Net Income (Loss) | |||
-44.86 |
-58.26 |
-52.45 |
-62.92 |
-73.48 |
-89.27 |
-121 |
-143 |
-159 |
-282 |
-281 |
-356 |
-324 |
-184 |
Net Income Including Noncontrolling Interests | |||
-44.86 |
-58.26 |
-52.45 |
-62.92 |
-73.48 |
-89.27 |
-121 |
-143 |
-159 |
-282 |
-281 |
-356 |
-324 |
-303 |
Net Income (Continuing Operations) | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-3.63 |
Net Income (Discontinued Operations) | |||
-44.86 |
-58.26 |
-52.45 |
-62.92 |
-73.48 |
-89.27 |
-121 |
-143 |
-159 |
-282 |
-281 |
-356 |
-324 |
-184 |
Net Income | |||
-8,054 |
-8,125 |
-8,500 |
-16,427 |
-24,492 |
-29,757 |
-46,026 |
-3,823 |
-38,603 |
-1,841 |
-362 |
-269 |
-138 |
-71.78 |
Net Margin % | |||
-- |
-- |
14.06 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- | Preferred Dividends | |||
-6.25 |
-8.12 |
0.02 |
-3.24 |
-3.02 |
-3.18 |
-4.01 |
-3.94 |
-3.67 |
-4.86 |
-4.17 |
-4.90 |
-3.83 |
-1.94 |
EPS (Basic) | |||
-6.25 |
-8.12 |
0.02 |
-3.24 |
-3.02 |
-3.18 |
-4.01 |
-3.94 |
-3.67 |
-4.86 |
-4.17 |
-4.90 |
-3.83 |
-1.94 |
EPS (Diluted) | |||
7.18 |
7.18 |
17.74 |
19.39 |
24.34 |
28.12 |
30.10 |
36.17 |
43.46 |
58.01 |
67.51 |
72.71 |
84.60 |
104 |
Shares Outstanding (Diluted Average) | |||
-27.07 |
-29.30 |
-37.28 |
-52.25 |
-72.29 |
-88.19 |
-120 |
-140 |
-159 |
-270 |
-275 |
-339 |
-304 |
-278 |
EBIT | |||
1.98 |
1.78 |
1.88 |
2.05 |
2.00 |
1.45 |
1.47 |
1.73 |
2.91 |
10.25 |
19.85 |
39.15 |
13.69 |
6.08 |
Depreciation, Depletion and Amortization | |||
-25.09 |
-27.52 |
-35.40 |
-50.19 |
-70.29 |
-86.74 |
-119 |
-138 |
-157 |
-259 |
-255 |
-300 |
-291 |
-269 |
EBITDA | |||
-4,504 |
-3,839 |
-5,738 |
-13,105 |
-23,430 |
-28,914 |
-45,291 |
-3,695 |
-37,898 |
-1,692 |
-328 |
-226 |
-124 |
-105 |
EBITDA Margin % | |||
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
Cashflow Statement | |||||||||||||||||
Dec11 |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
TTM | Fiscal Period | |||
-44.86 |
-58.26 |
-52.45 |
-62.92 |
-73.48 |
-89.27 |
-121 |
-143 |
-159 |
-282 |
-281 |
-356 |
-324 |
-184 |
Net Income From Continuing Operations | |||
1.98 |
1.78 |
1.88 |
2.05 |
2.00 |
1.45 |
1.47 |
1.73 |
2.91 |
10.25 |
19.85 |
39.15 |
13.69 |
6.08 |
Depreciation, Depletion and Amortization | |||
-- |
-- |
-- |
-- |
-- |
0.03 |
0.08 |
-26.95 |
27.00 |
-1.74 |
-1.52 |
-7.99 |
-16.34 |
-22.85 |
Change In Receivables | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-5.88 |
-4.28 |
-6.01 |
-14.91 |
-7.14 |
Change In Inventory | |||
-0.37 |
-1.13 |
0.42 |
-1.00 |
-0.19 |
-5.62 |
4.85 |
-2.91 |
-1.38 |
0.91 |
-1.75 |
3.60 |
-6.79 |
4.70 |
Change In Prepaid Assets | |||
0.87 |
4.00 |
-0.64 |
-1.09 |
2.49 |
8.46 |
1.92 |
3.18 |
3.21 |
17.91 |
5.00 |
10.12 |
1.88 |
-14.10 |
Change In Payables And Accrued Expense | |||
-0.57 |
-10.01 |
-2.64 |
-1.07 |
0.23 |
-0.10 |
-0.40 |
49.40 |
5.44 |
28.76 |
-2.23 |
0.95 |
-7.72 |
-0.40 |
Change In Other Working Capital | |||
-0.07 |
-7.13 |
-2.85 |
-3.16 |
2.52 |
2.76 |
6.44 |
22.72 |
34.27 |
39.97 |
-4.77 |
0.67 |
-43.88 |
-39.79 |
Change In Working Capital | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-2.72 |
-- |
-- |
-- |
-- | Deferred Tax | |||
0.27 |
0.08 |
0.55 |
6.53 |
12.39 |
11.95 |
13.23 |
16.27 |
17.92 |
36.45 |
43.43 |
52.34 |
47.81 |
28.22 |
Stock Based Compensation | |||
-- |
-- |
-- |
-- |
-- |
9.06 |
2.93 |
-- |
-- |
-- |
-- |
69.79 |
93.18 |
-- | Asset Impairment Charge | |||
14.26 |
24.61 |
5.11 |
2.42 |
0.90 |
4.23 |
1.18 |
-2.39 |
-1.83 |
19.64 |
1.26 |
0.93 |
-3.39 |
-0.96 |
Cash Flow from Others | |||
-28.41 |
-38.91 |
-47.76 |
-55.07 |
-55.67 |
-59.83 |
-95.34 |
-104 |
-106 |
-179 |
-222 |
-194 |
-217 |
-191 |
Cash Flow from Operations | |||
-0.15 |
-0.32 |
-6.48 |
-6.98 |
-3.33 |
-1.67 |
-2.53 |
-315 |
-3.23 |
-4.10 |
-10.38 |
-3.21 |
-6.89 |
-4.02 |
Purchase Of Property, Plant, Equipment | |||
-- |
-- |
-- |
-- |
-- |
0.00 |
-- |
1.54 |
0.01 |
-- |
-- |
-- |
-- |
-- | Sale Of Property, Plant, Equipment | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-0.82 |
-- |
-- |
-- |
-- | Purchase Of Business | |||
-- |
-- |
-- |
-- |
-54.09 |
-281 |
-36.03 |
-6.99 |
-331 |
-259 |
-184 |
-348 |
-264 |
-311 |
Purchase Of Investment | |||
-- |
-- |
-- |
-- |
1.00 |
209 |
157 |
213 |
317 |
276 |
172 |
232 |
385 |
313 |
Sale Of Investment | |||
-- |
-- |
-- |
-- |
-- |
-1.80 |
-0.10 |
-0.10 |
-- |
-0.12 |
-- |
-- |
-- |
-- | Net Intangibles Purchase And Sale | |||
0.08 |
0.08 |
0.08 |
-- |
0.00 |
-0.00 |
0.00 |
-0.00 |
-0.01 |
0.00 |
-7.70 |
-19.80 |
-4.88 |
-10.63 |
Cash From Other Investing Activities | |||
-0.08 |
-0.24 |
-6.40 |
-6.98 |
-56.42 |
-75.50 |
119 |
-107 |
-17.59 |
12.13 |
-29.67 |
-139 |
110 |
-12.94 |
Cash Flow from Investing | |||
-- |
-- |
-- |
235 |
136 |
-- |
196 |
-- |
223 |
83.95 |
21.71 |
248 |
100 |
97.63 |
Issuance of Stock | |||
-- |
-- |
40.65 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- | Net Issuance of Preferred Stock | |||
67.15 |
18.17 |
21.90 |
6.75 |
9.83 |
-- |
-- |
-- |
-- |
288 |
-- |
98.15 |
48.42 |
-- | Issuance of Debt | |||
-13.08 |
-4.56 |
-8.58 |
-12.54 |
-5.25 |
-3.54 |
-3.64 |
-0.93 |
-- |
-- |
-- |
-11.10 |
-18.26 |
-16.58 |
Payments of Debt | |||
54.07 |
13.61 |
13.33 |
-5.79 |
4.58 |
-3.54 |
-3.64 |
-0.93 |
-- |
288 |
-- |
87.05 |
30.16 |
-16.58 |
Net Issuance of Debt | |||
-- |
0.01 |
0.02 |
0.33 |
1.76 |
0.90 |
3.35 |
2.71 |
-1.18 |
-39.96 |
8.16 |
-3.37 |
6.22 |
0.66 |
Other Financing | |||
54.07 |
13.62 |
53.99 |
229 |
143 |
-2.64 |
196 |
1.78 |
222 |
331 |
29.87 |
332 |
137 |
81.70 |
Cash Flow from Financing | |||
4.04 |
29.62 |
4.08 |
4.50 |
172 |
202 |
64.08 |
283 |
73.99 |
172 |
337 |
116 |
115 |
187 |
Beginning Cash Position | |||
25.58 |
-25.54 |
-0.17 |
167 |
30.51 |
-138 |
219 |
-209 |
97.90 |
165 |
-221 |
-0.65 |
29.73 |
-122 |
Net Change in Cash | |||
29.62 |
4.08 |
3.91 |
172 |
202 |
64.08 |
283 |
73.99 |
172 |
337 |
116 |
115 |
145 |
64.61 |
Ending Cash Position | |||
-0.15 |
-0.32 |
-6.48 |
-6.98 |
-3.33 |
-3.47 |
-2.63 |
-315 |
-3.23 |
-4.22 |
-10.38 |
-3.21 |
-6.89 |
-4.02 |
Capital Expenditure | |||
-28.56 |
-39.23 |
-54.24 |
-62.05 |
-59.00 |
-63.30 |
-97.97 |
-419 |
-109 |
-183 |
-232 |
-197 |
-223 |
-195 |
Free Cash Flow | |||
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
Balance Sheet | |||||||||||||||||
Dec11 |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
TTM | Fiscal Period | |||
29.62 |
4.08 |
3.91 |
171 |
202 |
63.50 |
283 |
73.26 |
171 |
334 |
111 |
109 |
137 |
58.59 |
Cash And Cash Equivalents | |||
-- |
-- |
-- |
-- |
50.69 |
122 |
-- |
103 |
119 |
103 |
114 |
232 |
117 |
125 |
Marketable Securities | |||
29.62 |
4.08 |
3.91 |
171 |
252 |
186 |
283 |
176 |
290 |
437 |
225 |
341 |
254 |
184 |
Cash, Cash Equivalents, Marketable Securities | |||
-- |
0.08 |
0.23 |
0.30 |
0.08 |
0.13 |
0.05 |
27.00 |
-- |
1.83 |
3.35 |
11.34 |
27.68 |
48.26 |
Accounts Receivable | |||
-- |
-- |
-- |
-- |
0.08 |
5.90 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- | Other Current Receivables | |||
-- |
0.08 |
0.23 |
0.30 |
0.16 |
6.03 |
0.05 |
27.00 |
-- |
1.83 |
3.35 |
11.34 |
27.68 |
48.26 |
Total Receivables | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
0.51 |
3.94 |
3.73 |
Inventories, Raw Materials & Components | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
4.93 |
17.42 |
44.08 |
Inventories, Work In Process | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
10.15 |
12.89 |
24.22 |
37.41 |
Inventories, Finished Goods | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
5.88 |
-- |
-- |
0.00 |
-- | Inventories, Other | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
5.88 |
10.15 |
18.33 |
45.58 |
85.21 |
Total Inventories | |||
0.50 |
1.25 |
0.68 |
1.40 |
1.50 |
1.14 |
2.27 |
5.11 |
6.49 |
5.79 |
7.54 |
4.36 |
11.70 |
12.14 |
Other Current Assets | |||
30.12 |
5.41 |
4.81 |
173 |
254 |
193 |
285 |
208 |
297 |
450 |
246 |
375 |
339 |
330 |
Total Current Assets | |||
-- |
-- |
-- |
-- |
1.75 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- | Investments And Advances | |||
0.81 |
0.92 |
0.95 |
1.01 |
13.54 |
13.58 |
14.19 |
14.74 |
23.86 |
29.48 |
37.40 |
41.42 |
-- |
-- | Machinery, Furniture, Equipment | |||
0.25 |
0.33 |
8.88 |
13.42 |
13.48 |
4.95 |
4.34 |
8.93 |
2.39 |
1.54 |
3.11 |
1.61 |
-- |
-- | Construction In Progress | |||
11.99 |
12.09 |
12.68 |
14.75 |
4.16 |
4.21 |
4.26 |
4.75 |
31.91 |
35.60 |
51.82 |
16.39 |
90.21 |
76.99 |
Other Gross PPE | |||
13.04 |
13.34 |
22.50 |
29.18 |
31.18 |
22.74 |
22.78 |
28.42 |
58.15 |
66.62 |
92.33 |
59.42 |
90.21 |
76.99 |
Gross Property, Plant and Equipment | |||
-4.60 |
-6.36 |
-8.19 |
-9.91 |
-11.47 |
-12.16 |
-13.53 |
-13.97 |
-16.87 |
-19.49 |
-23.33 |
-28.59 |
-- |
-- | Accumulated Depreciation | |||
8.44 |
6.98 |
14.32 |
19.27 |
19.71 |
10.59 |
9.25 |
14.45 |
41.29 |
47.13 |
69.00 |
59.42 |
90.21 |
76.99 |
Property, Plant and Equipment | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
218 |
202 |
113 |
9.81 |
7.63 |
Intangible Assets | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
147 |
147 |
77.18 |
-- |
-- | Goodwill | |||
1.37 |
1.04 |
3.52 |
0.46 |
0.40 |
1.08 |
1.24 |
3.98 |
2.40 |
4.78 |
13.75 |
35.24 |
39.57 |
47.25 |
Other Long Term Assets | |||
9.81 |
8.02 |
17.83 |
19.74 |
21.86 |
11.67 |
10.49 |
18.43 |
43.69 |
270 |
285 |
207 |
140 |
132 |
Total Long-Term Assets | |||
39.93 |
13.42 |
22.65 |
192 |
276 |
204 |
296 |
226 |
340 |
720 |
531 |
582 |
478 |
462 |
Total Assets | |||
0.78 |
1.81 |
5.53 |
3.15 |
2.66 |
3.75 |
6.81 |
8.43 |
8.01 |
12.66 |
10.60 |
4.55 |
13.81 |
12.34 |
Accounts Payable | |||
1.99 |
5.11 |
3.28 |
1.61 |
2.27 |
8.64 |
5.75 |
7.66 |
10.50 |
14.09 |
15.36 |
28.03 |
19.51 |
22.43 |
Current Accrued Expense | |||
2.77 |
6.91 |
8.80 |
4.76 |
4.92 |
12.39 |
12.56 |
16.10 |
18.51 |
26.75 |
25.96 |
32.58 |
33.32 |
34.76 |
Accounts Payable & Accrued Expense | |||
3.46 |
94.51 |
22.86 |
2.64 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
2.50 |
10.15 |
Short-Term Debt | |||
1.09 |
0.94 |
-- |
0.31 |
3.14 |
3.48 |
1.87 |
-- |
3.47 |
4.44 |
4.75 |
4.91 |
8.35 |
17.21 |
Short-Term Capital Lease Obligation | |||
4.55 |
95.45 |
22.86 |
2.94 |
3.14 |
3.48 |
1.87 |
-- |
3.47 |
4.44 |
4.75 |
4.91 |
10.85 |
27.36 |
Short-Term Debt & Capital Lease Obligation | |||
0.50 |
-- |
0.08 |
-- |
-- |
-- |
-- |
8.59 |
7.91 |
7.85 |
9.36 |
6.87 |
10.74 |
6.33 |
Current Deferred Revenue | |||
0.50 |
-- |
0.08 |
-- |
-- |
-- |
-- |
8.59 |
7.91 |
7.85 |
9.36 |
6.87 |
10.74 |
6.33 |
DeferredTaxAndRevenue | |||
1.03 |
15.57 |
15.82 |
2.54 |
3.98 |
3.78 |
6.47 |
7.28 |
11.09 |
21.93 |
27.22 |
31.33 |
34.32 |
11.60 |
Other Current Liabilities | |||
8.86 |
118 |
47.56 |
10.24 |
12.04 |
19.65 |
20.90 |
31.97 |
40.98 |
60.96 |
67.29 |
75.68 |
89.22 |
80.05 |
Total Current Liabilities | |||
63.49 |
11.00 |
2.63 |
-- |
-- |
-- |
-- |
-- |
-- |
181 |
281 |
379 |
427 |
421 |
Long-Term Debt | |||
0.94 |
0.01 |
-- |
0.60 |
5.35 |
1.87 |
-- |
-- |
25.87 |
27.15 |
39.13 |
34.18 |
40.99 |
35.04 |
Long-Term Capital Lease Obligation | |||
64.44 |
11.00 |
2.63 |
0.60 |
5.35 |
1.87 |
-- |
-- |
25.87 |
208 |
320 |
414 |
468 |
456 |
Long-Term Debt & Capital Lease Obligation | |||
-0.44 |
-0.49 |
-0.16 |
0.02 |
0.03 |
0.03 |
0.01 |
-- |
0.13 |
0.57 |
4.74 |
33.21 |
-3.16 |
-2.97 |
Debt-to-Equity | |||
12.81 |
3.04 |
3.18 |
3.73 |
3.77 |
3.65 |
3.34 |
46.00 |
47.95 |
77.29 |
74.15 |
78.58 |
70.42 |
85.55 |
NonCurrent Deferred Liabilities | |||
109 |
98.17 |
127 |
1.54 |
1.41 |
2.12 |
2.61 |
2.75 |
-0.00 |
0.00 |
1.49 |
1.48 |
2.83 |
2.91 |
Other Long-Term Liabilities | |||
187 |
112 |
133 |
5.86 |
10.53 |
7.64 |
5.95 |
48.76 |
73.82 |
285 |
395 |
494 |
541 |
545 |
Total Long-Term Liabilities | |||
195 |
230 |
180 |
16.10 |
22.57 |
27.29 |
26.85 |
80.73 |
115 |
346 |
463 |
569 |
630 |
625 |
Total Liabilities | |||
-- |
-- |
-- |
0.02 |
0.03 |
0.03 |
0.04 |
0.04 |
0.05 |
0.07 |
0.07 |
0.08 |
0.09 |
0.11 |
Common Stock | |||
-160 |
-218 |
-196 |
-259 |
-332 |
-422 |
-542 |
-685 |
-844 |
-1,126 |
-1,398 |
-1,754 |
-2,078 |
-2,207 |
Retained Earnings | |||
-- |
-- |
-- |
-- |
-0.04 |
-0.05 |
-- |
-0.01 |
0.00 |
-- |
-0.02 |
-0.37 |
0.01 |
0.07 |
Accumulated other comprehensive income (loss) | |||
4.59 |
1.60 |
38.33 |
435 |
586 |
599 |
811 |
830 |
1,070 |
1,501 |
1,466 |
1,767 |
1,927 |
2,044 |
Additional Paid-In Capital | |||
-- |
-- |
-0.00 |
0.00 |
-0.00 |
-- |
-- |
-0.00 |
0.00 |
0.00 |
0.00 |
-0.00 |
0.00 |
-0.00 |
Other Stockholders Equity | |||
-155 |
-217 |
-158 |
176 |
253 |
177 |
269 |
146 |
225 |
374 |
68.47 |
12.60 |
-152 |
-163 |
Total Stockholders Equity | |||
-155 |
-217 |
-158 |
176 |
253 |
177 |
269 |
146 |
225 |
374 |
68.47 |
12.60 |
-152 |
-163 |
Total Equity | |||
-3.89 |
-16.15 |
-6.96 |
0.92 |
0.92 |
0.87 |
0.91 |
0.64 |
0.66 |
0.52 |
0.13 |
0.02 |
-0.32 |
-0.35 |
Equity-to-Asset | |||
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
Valuation Ratios | |||||||||||||||||
Dec11 |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
TTM | Fiscal Period | |||
N/A |
N/A |
N/A |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss | PE Ratio | |||
N/A |
N/A |
N/A |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss |
At Loss | PE Ratio without NRI | |||
-- |
-- |
-- |
2.28 |
3.82 |
3.35 |
4.86 |
5.11 |
3.77 |
5.24 |
17.05 |
121 |
-- |
-- | PB Ratio | |||
-- |
-- |
-- |
2.28 |
3.82 |
3.35 |
4.86 |
5.11 |
3.77 |
12.57 |
-- |
-- |
-- |
-- | Price-to-Tangible-Book | |||
-- |
-- |
-- |
847 |
2,847 |
1,882 |
3,972 |
195 |
1,623 |
107 |
14.17 |
10.13 |
3.18 |
1.36 |
PS Ratio | |||
-- |
-- |
-- |
614 |
2,408 |
1,376 |
3,910 |
152 |
1,427 |
113 |
16.29 |
12.06 |
4.26 |
2.65 |
EV-to-Revenue | |||
-- |
-- |
-- |
-4.69 |
-10.28 |
-4.76 |
-8.63 |
-4.13 |
-3.76 |
-6.70 |
-4.97 |
-5.33 |
-3.43 |
-2.53 |
EV-to-EBITDA | |||
-- |
-- |
-- |
-4.50 |
-9.99 |
-4.68 |
-8.53 |
-4.07 |
-3.70 |
-6.44 |
-4.61 |
-4.71 |
-3.28 |
-2.44 |
EV-to-EBIT | |||
-- |
-- |
-- |
-3.79 |
-12.25 |
-6.52 |
-10.46 |
-1.36 |
-5.39 |
-9.50 |
-5.47 |
-8.12 |
-4.46 |
-3.49 |
EV-to-FCF | |||
-- |
-- |
-- |
-22.22 |
-10.01 |
-21.37 |
-11.72 |
-24.57 |
-27.03 |
-15.53 |
-21.69 |
-21.23 |
-30.49 |
-40.98 |
Earnings Yield (Joel Greenblatt) % | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
3.49 |
1.61 |
0.76 |
Cyclically Adjusted PB Ratio | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
49.73 |
13.33 |
4.26 |
Cyclically Adjusted PS Ratio | |||
-- |
-- |
-- |
-15.41 |
-6.11 |
-10.67 |
-7.50 |
-56.33 |
-12.87 |
-9.32 |
-19.85 |
-12.94 |
-28.90 |
-51.15 |
FCF Yield % | |||
Valuation and Quality | |||||||||||||||||
Dec11 |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
TTM | Fiscal Period | |||
-- |
-- |
-- |
403 |
966 |
593 |
1,305 |
744 |
850 |
1,961 |
1,168 |
1,521 |
773 |
381 |
Market Cap | |||
-- |
-- |
-- |
235 |
722 |
413 |
1,024 |
568 |
589 |
1,736 |
1,268 |
1,599 |
998 |
680 |
Enterprise Value | |||
-- |
-- |
-- |
16.94 |
34.16 |
20.70 |
35.75 |
20.13 |
16.23 |
28.34 |
16.32 |
18.46 |
8.79 |
3.65 |
Month End Stock Price | |||
-23.10 |
-31.50 |
-9.93 |
6.52 |
8.12 |
5.52 |
7.01 |
2.57 |
3.35 |
1.31 |
-3.32 |
-2.77 |
-4.28 |
-4.20 |
Net Cash per Share | |||
-23.03 |
-31.31 |
-9.88 |
6.59 |
8.18 |
5.77 |
7.08 |
3.44 |
3.47 |
1.50 |
-3.03 |
-2.36 |
-3.31 |
-2.81 |
Net Current Asset Value | |||
-23.10 |
-31.49 |
-9.93 |
6.53 |
8.12 |
5.53 |
7.01 |
3.12 |
3.35 |
1.37 |
-3.21 |
-2.56 |
-3.78 |
-3.45 |
Net-Net Working Capital | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-29.12 |
-23.70 |
-17.93 |
-24.27 |
-23.65 |
-26.57 |
-24.25 |
Intrinsic Value: Projected FCF | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
1,399 |
1,138 |
Median PS Value | |||
-- |
-- |
-- |
-- |
-- |
-- |
-23.19 |
-88.62 |
-80.04 |
-224 |
-835 |
-1,022 |
-1,683 |
-1,230 |
Earnings Power Value (EPV) | |||
-- |
-- |
-19.78 |
13.25 |
24.19 |
9.74 |
26.33 |
0.21 |
0.33 |
0.65 |
-3.33 |
-3.70 |
-6.33 |
-7.11 |
Altman Z-Score | |||
N/A |
N/A |
N/A |
4.00 |
3.00 |
3.00 |
4.00 |
4.00 |
2.00 |
3.00 |
4.00 |
3.00 |
4.00 |
3.00 |
Piotroski F-Score | |||
-- |
-- |
-- |
-2.31 |
-2.52 |
30.84 |
-3.91 |
45.15 |
-6.84 |
46.44 |
-0.04 |
-1.79 |
-1.71 |
-0.41 |
Beneish M-Score | |||
-2.91 |
-2.86 |
-10.13 |
0.39 |
0.05 |
-0.01 |
-0.06 |
-0.10 |
-0.16 |
0.44 |
0.23 |
0.17 |
0.13 |
0.28 |
Scaled Net Operating Assets | |||
-41.01 |
-142 |
7.56 |
-0.45 |
14.00 |
22.54 |
-48.71 |
30.35 |
-10.48 |
-16.07 |
-5.67 |
-4.14 |
-45.39 |
4.20 |
Sloan Ratio % | |||
3.40 |
0.05 |
0.10 |
16.87 |
21.10 |
9.81 |
13.65 |
6.50 |
7.24 |
7.38 |
3.66 |
4.95 |
3.80 |
4.12 |
Current Ratio | |||
3.40 |
0.05 |
0.10 |
16.87 |
21.10 |
9.81 |
13.65 |
6.50 |
7.24 |
7.29 |
3.51 |
4.71 |
3.29 |
3.05 |
Quick Ratio | |||
3.35 |
0.03 |
0.08 |
16.71 |
20.96 |
9.44 |
13.53 |
5.50 |
7.08 |
7.16 |
3.34 |
4.50 |
2.85 |
2.30 |
Cash Ratio | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
N/A |
-- |
-- |
-- |
-- |
-- | Interest Coverage | |||
-- |
-- |
-- |
38.90 |
40.78 |
33.59 |
36.30 |
37.40 |
20.39 |
34.30 |
33.21 |
30.66 |
37.61 |
7.56 |
Highest Stock Price | |||
-- |
-- |
-- |
14.89 |
15.02 |
12.55 |
18.30 |
18.06 |
10.22 |
12.46 |
12.46 |
11.52 |
5.81 |
2.30 |
Lowest Stock Price | |||
-- |
-- |
-147 |
-33.98 |
-18.99 |
-1.28 |
-27.46 |
-1.26 |
-41.65 |
-32.08 |
-3.48 |
-15.09 |
-6.77 |
-19.45 |
Shares Buyback Ratio % | |||
-- |
-- |
-- |
-58.24 |
-14.10 |
-- |
-15.03 |
-- |
-26.22 |
-4.28 |
-1.86 |
-16.31 |
-12.96 |
-25.62 |
Buyback Yield % | |||
-- |
28.21 |
-65.00 |
-42.86 |
-40.00 |
-8.33 |
-18.18 |
1,044 |
-90.29 |
2,540 |
336 |
58.25 |
51.73 |
9.18 |
YoY Rev. per Sh. Growth | |||
-- |
-29.93 |
100 |
-21,700 |
6.79 |
-5.30 |
-26.10 |
1.75 |
6.85 |
-32.43 |
14.20 |
-17.51 |
21.84 |
61.12 |
YoY EPS Growth | |||
-- |
-9.70 |
47.98 |
-29.72 |
-11.59 |
-6.82 |
-27.78 |
3.35 |
5.49 |
-24.13 |
15.44 |
-9.18 |
16.77 |
0.64 |
YoY EBITDA Growth | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-5.04 |
-9.44 |
-7.10 |
-4.22 |
0.47 |
2.47 |
0.80 |
5-Year EBITDA Growth Rate | |||
7.18 |
7.18 |
17.74 |
19.39 |
24.34 |
28.12 |
30.10 |
36.17 |
43.46 |
58.01 |
67.51 |
72.71 |
84.60 |
104 |
Shares Outstanding (Basic Average) | |||
7.18 |
7.18 |
17.74 |
23.77 |
28.29 |
28.65 |
36.52 |
36.98 |
52.38 |
69.18 |
71.58 |
82.39 |
87.96 |
104 |
Shares Outstanding (EOP) | |||
-- |
-- |
-- |
-- |
-- |
-- |
1.95 |
1.41 |
0.73 |
1.20 |
1.01 |
0.53 |
0.48 |
-- | Beta | |||
03/28/14 |
02/06/14 |
03/28/14 |
03/04/15 |
03/04/16 |
02/28/17 |
03/02/18 |
02/28/19 |
02/26/20 |
02/25/21 |
02/28/22 |
02/28/23 |
02/28/24 |
Filing Date | ||||
03/28/14 |
03/04/15 |
03/04/16 |
02/28/17 |
03/02/18 |
02/28/19 |
02/26/20 |
02/25/21 |
02/28/22 |
02/28/23 |
02/28/24 |
02/28/24 |
02/28/24 |
Restated Filing Date | ||||
02/27/17 |
02/28/18 |
02/27/19 |
02/24/20 |
02/22/21 |
02/28/22 |
02/28/23 |
02/28/24 |
Earnings Release Date | |||||||||
-- |
-- |
-- |
65.00 |
46.00 |
40.00 |
30.00 |
25.00 |
18.00 |
113 |
82.00 |
180 |
155 |
155 |
Number of Shareholders | |||
-- |
-- |
62.00 |
83.00 |
103 |
106 |
134 |
170 |
193 |
470 |
495 |
534 |
597 |
597 |
Number of Employees | |||
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
Business Segments | |||||||||||||||||
Dec11 |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
TTM | Fiscal Period | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
0.41 |
14.91 |
76.48 |
126 |
222 |
122 |
Product Segment | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
0.42 |
1.32 |
6.99 |
12.25 |
4.97 |
Service Segment | |||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
3.73 |
0.41 |
-- |
-- |
-- |
-- |
-- | Milestone | |||
-- |
-- |
-- |
-- |
-- |
0.30 |
0.26 |
-- |
-- |
-- |
-- |
-- |
-- |
-- | Relastin Royalty | |||
Geographic Segments | |||||||||||||||||
Dec11 |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
TTM | Fiscal Period | |||
-- |
-- |
-- |
-- |
-- |
0.30 |
0.26 |
3.73 |
0.41 |
15.33 |
77.80 |
133 |
234 |
-- | United States | |||
|
GuruFocus Manual of Stocks™ | Jul 05, 2025
Revance Therapeutics Inc (NAS:RVNC)
|
www.gurufocus.com/stock/NAS:RVNC/summary | |
GuruFocus Predictability Rank is a proprietary ranking of the consistency of a business. We rank the predictability of companies based on the consistency of their revenue per share and EBITDA (earnings before interest, tax, depreciation and amortization) per share over the past 10 fiscal years. Our study found that there is a strong correlation between the stock performance and the predictability of a business. Over the long term, companies with higher predictability also have better stock performance.
The rank is from 1-star to 5-star, with 5-star as the best.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
The rank is from 1 to 10, with 10 as the highest.
A Financial Strength rank of 8 or above indicates good financial strength; between 4-7 indicates fair financial strength; 3 or below means poor financial strength.
GuruFocus Profitability Rank indicates how profitable a company is and how likely it is that the company's business will stay that way. It is based on these factors:
The rank is from 1 to 10, with 10 as the highest.
A Profitability Rank of 8 or above indicates good profitability; between 4-7 indicates fair profitability; 3 or below means poor profitability.
In Peter Lynch's excellent book, "One Up on Wall Street," he used many charts to illustrate the valuation of stocks. “A quick way to tell if a stock is overpriced is to compare the price line to the earnings line. If you bought familiar growth companies – such as Shoney’s, The Limited, or Marriott – when the stock price fell well below the earnings line, and sold them when the stock price rose dramatically above it, the chances are you’d do pretty well.”
The original Peter Lynch Chart does have limitations due to the right side price scale is pre-set at 15 times the earnings scale on the left side. When the stock price and earnings line coincide, the price-to-earnings ratio is always 15 times. Instead of using the fixed PE Ratio of 15, our approach is using 15-year historical median PE without NRI Ratio for each stock.
The Peter Lynch Chart with earnings line at median PE without NRI ratio works well for the companies with steady growth and earnings trends, or the stalwarts, as coined by Lynch. These companies tend to be found in sectors such as consumer staples, healthcare, and utilities, where the consumption of the product or service is relatively independent of economic conditions. It does not work well with the sectors that are cyclical: industrials, chemicals, durable goods, and so forth.
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:
GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.